Trial Profile
Feasibility Study on Adjuvant Carboplatin and S-1 in patients with completely resected stage II-IIIA Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2014
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Carboplatin
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Dec 2014 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 14 Sep 2013 New trial record